The constructed HER2/neu peptide-based vaccine candidates were administered in both prophylactic and therapeutic vaccination settings in the TUBO tumor model of BALB/c mice, which overexpresses the HER2/neu oncogene. The gene discussed is ERBB2; the disease is neoplasm.